conducted a randomized phase II trial that compared autologous tumor cell vaccine (TC) with autologous tumor cells loaded onto dendritic cells (DCV) admixed with GM-CSF protein in 42 patients with metastatic melanoma (47–49). The gene discussed is CSF2; the disease is metastatic melanoma.